| Systematic (IUPAC) name | |
|---|---|
| [1-methyl-5-({3-[3-(piperidin-1-ylmethyl)phenoxy]propyl}amino)-1H-1,2,4-triazol-3-yl]methanol | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Uncontrolled |
| Routes | Oral |
| Identifiers | |
| CAS number | 76956-02-0 |
| ATC code | None |
| PubChem | CID 55473 |
| ChemSpider | 50093 |
| UNII | X16K5179V5 |
| Chemical data | |
| Formula | C19H29N5O2 |
| Mol. mass | 359.47 g/mol |
| SMILES | eMolecules & PubChem |
Lavoltidine (INN, USAN, BAN; code name AH-23,844), previously known as loxtidine, is a highly potent and selective H2 receptor antagonist which was under development as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.[1][2]
|
||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)